TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06366464: A Study of Pitolisant in Patients With Prader-Willi Syndrome

Sponsor: Harmony Biosciences Management, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 134 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,630,088

Rescue Site Savings

+$2,404,344

Unlock Full NCT06366464 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06366464 Rescue Dossier →